Vitamin D Personalized Dosing: Why 600 IU Is the Wrong Number for Most Adults

Roughly 40 percent of US adults have serum 25-hydroxyvitamin D below 30 ng/mL — the Endocrine Society's threshold for sufficiency. About 70 percent fall below the 40-60 ng/mL range that longevity-focused clinicians (Attia, Holick, Bischoff-Ferrari) target as optimal. And yet the RDA — 600 IU daily for adults under 70, 800 IU for adults over 70 — was set in 2010 to prevent rickets and osteomalacia, not to optimize the immune, cardiovascular, and bone-health endpoints the modern vitamin D literature has connected to higher serum levels.

The gap between the RDA and what most longevity-focused clinicians actually target is one of the larger gulfs in modern preventive nutrition. The deficiency is common. The cost of fixing it is trivial. The testing is cheap and widely available. And yet most US adults have either never had their 25-hydroxyvitamin D measured or are dosing far below what their actual serum level would require.

What follows: the biology of why serum vitamin D matters across multiple longevity-relevant systems, the published threshold targets that emerge from the cohort and intervention literature, the dose-response framework for moving serum levels into the target range, the form selection (D3 vs D2), the cofactor dependencies (K2 and magnesium) that determine whether oral vitamin D actually does what it should, and how to integrate vitamin D status into the broader biomarker stack.

The Biology — Why Serum Vitamin D Matters Across Multiple Systems

Vitamin D's classical role is calcium homeostasis. Active 1,25-dihydroxyvitamin D (calcitriol) upregulates intestinal calcium absorption, mobilizes calcium from bone when serum calcium falls, and supports renal calcium reabsorption. This is the rickets-prevention biology that drove the original RDA — without sufficient vitamin D, calcium absorption falls below what's needed for skeletal mineralization.

The modern vitamin D literature has expanded the relevant biology dramatically. The vitamin D receptor (VDR) is expressed in approximately 30 different tissue types beyond bone and intestine — immune cells, cardiac muscle, vascular endothelium, neurons, beta cells in the pancreas. Active calcitriol modulates expression of more than 200 genes. The functions that matter at the population level extend well beyond bone:

Immune function. The vitamin D status of macrophages and T cells affects both innate antimicrobial response and adaptive autoimmune regulation. Adults with low 25-hydroxyvitamin D show higher rates of respiratory infections, more autoimmune progression, and slower vaccine response. The Bischoff-Ferrari work on vitamin D and falls in older adults overlaps with immune-mediated muscle function.

Cardiovascular function. The Mendelian randomization analyses on 25-hydroxyvitamin D and cardiovascular endpoints have produced mixed results — population-level studies show associations but causal inference is contested. The supportive interpretation is that vitamin D affects vascular endothelium and renin-angiotensin regulation; the conservative interpretation is that vitamin D status is a marker of broader health behaviors. Both can be partially true.

Cognitive function. The vitamin D receptor is expressed in the hippocampus and other brain regions implicated in memory and executive function. Cohort studies (Annweiler et al., Littlejohns et al.) show associations between low 25-hydroxyvitamin D and accelerated cognitive decline, particularly in adults below 30 ng/mL. The intervention trial data is preliminary but mechanistically supported.

Bone health and falls. The original rationale for vitamin D RDA setting. Bischoff-Ferrari's meta-analyses establish that 800-2000 IU daily supplementation reduces hip fracture risk in older adults, with the effect concentrated in adults who started deficient. The intervention works best when serum 25-hydroxyvitamin D is raised above 30 ng/mL.

Mood and depression. The 25-hydroxyvitamin D status correlates with depressive symptoms in cohort data, particularly in winter months in northern latitudes. The supplementation intervention trials show modest benefit in adults with both deficiency and mood symptoms.

The integrated picture is not "vitamin D fixes everything" — that overinterpretation has caused real damage to the field. The accurate picture is that vitamin D status modestly affects many systems, and the cumulative effect of bringing a deficient adult into the sufficient range produces measurable benefits across multiple endpoints.

The Threshold Targets That Matter

The reference framework for serum 25-hydroxyvitamin D has converged over the past decade, though disagreements persist between bodies:

• Below 20 ng/mL (50 nmol/L) — Deficient. Both the Institute of Medicine (now National Academies) and the Endocrine Society agree this is the deficiency threshold. Risk of osteomalacia, secondary hyperparathyroidism, and impaired calcium absorption is elevated. Roughly 25 percent of US adults sit below this line.
• 20-30 ng/mL (50-75 nmol/L) — Insufficient (Endocrine Society) or sufficient (IOM). The two bodies disagree. IOM considers 20 ng/mL adequate for skeletal health in healthy adults. Endocrine Society and most longevity-focused clinicians consider this zone insufficient for the broader extra-skeletal benefits. Approximately another 15-20 percent of US adults sit here.
• 30-40 ng/mL (75-100 nmol/L) — Sufficient (both bodies agree). The minimum target for most adults. Bone health and basic immune function are well-supported in this zone.
• 40-60 ng/mL (100-150 nmol/L) — Optimal for longevity. The target zone most longevity-focused clinicians (Attia, Holick) recommend. The Endocrine Society's upper guidance is consistent with this range. Roughly 10-15 percent of US adults sit here naturally.
• 60-100 ng/mL (150-250 nmol/L) — Upper safe range. No documented toxicity in this zone in adults without underlying calcium dysregulation. The marginal benefit above 60 ng/mL is small relative to the gain from moving from 20 to 40.
• Above 100 ng/mL (250 nmol/L) — Caution zone. Risk of hypercalcemia rises, particularly in adults supplementing high doses without monitoring serum calcium. Sustained levels above 150 ng/mL produce frank toxicity in some individuals.

The longevity-protocol target that emerges from this framework: 40-60 ng/mL serum 25-hydroxyvitamin D. Not the IOM minimum, not the dramatic upper end — the well-validated zone where the extra-skeletal benefits are realized without raising toxicity concerns.

The Dose-Response — Moving Serum Levels

The published dose-response data on vitamin D supplementation produces a workable approximation that has held up across multiple trials:

Heaney's rule of thumb: For each 100 IU of daily vitamin D3 supplementation, serum 25-hydroxyvitamin D rises by approximately 1 ng/mL at steady state in adults starting from typical baseline. The relationship is roughly linear up to 4,000-5,000 IU daily, with diminishing returns above that range.

The practical translation for adults running a longevity protocol:

• Baseline 25-OH-D below 20 ng/mL: 5,000-10,000 IU daily for 8-12 weeks to reach 40 ng/mL, then 2,000-4,000 IU daily for maintenance. Retest at 12 weeks.
• Baseline 25-OH-D 20-30 ng/mL: 4,000-5,000 IU daily for 12 weeks to reach 40-50 ng/mL, then 2,000-3,000 IU for maintenance.
• Baseline 25-OH-D 30-40 ng/mL: 2,000-3,000 IU daily to reach and maintain 40-50 ng/mL.
• Baseline 25-OH-D above 40 ng/mL: 1,000-2,000 IU daily maintenance, with seasonal adjustment (winter higher, summer lower if sunlight exposure is meaningful).

These ranges represent typical adult responses. Individual variation is substantial — body weight, GI absorption capacity, genetic VDR and CYP2R1 variants, and concurrent medications all affect the dose-to-serum relationship. This is why testing matters more than the dose label. The same 5,000 IU produces 50 ng/mL in one adult and 35 ng/mL in another. The data closes the loop only with the 12-week retest.

D3 vs D2 — The Form Choice That Actually Matters

Two forms dominate the supplement market:

Cholecalciferol (vitamin D3). The form produced in human skin under UVB exposure and the form present in animal-derived dietary sources (fatty fish, egg yolks). Multiple head-to-head trials (Tripkovic et al. 2012 meta-analysis) establish that D3 raises serum 25-hydroxyvitamin D approximately twice as effectively as the same dose of D2 over the same time window. D3 also has a longer half-life in circulation, producing more stable serum levels with daily or weekly dosing.

Ergocalciferol (vitamin D2). The plant-derived form, typically produced by UV irradiation of yeast or mushrooms. Less effective per unit dose than D3 at raising serum 25-hydroxyvitamin D. Still effective when used at higher doses (e.g., the prescription 50,000 IU weekly protocol uses D2 historically), but the modern consumer recommendation strongly favors D3.

For the longevity protocol: vitamin D3 (cholecalciferol). The supplement market has largely standardized on D3, but the older "vitamin D" label on grocery-store multivitamins sometimes still indicates D2 — worth checking the supplement facts panel rather than the front label.

The Cofactor Dependencies — K2 and Magnesium

The longevity-focused vitamin D literature has increasingly emphasized that oral D3 supplementation doesn't work in isolation. Two cofactors meaningfully affect whether the supplemented vitamin D actually does what it's supposed to:

Magnesium. The conversion of vitamin D to its active 1,25-dihydroxyvitamin D form requires magnesium-dependent enzymes. Adults who are magnesium-deficient may supplement vitamin D and see serum 25-hydroxyvitamin D rise but fail to see the downstream calcium handling and immune effects properly. Given that roughly 50 percent of US adults consume below the EAR for magnesium, this is a real concern. The pragmatic intervention: 300-400 mg magnesium glycinate daily alongside vitamin D supplementation.

Vitamin K2 (specifically the MK-7 form). Vitamin D upregulates calcium absorption. K2 directs that calcium into bone (via osteocalcin) and away from arterial walls (via matrix Gla protein). Without sufficient K2, vitamin D-driven calcium absorption may produce arterial calcification as a side effect — which is precisely what longevity protocols are trying to prevent. The intervention literature on K2 is less mature than on D3 itself, but the mechanistic case is strong, the safety profile is excellent, and the practical recommendation has converged on 100-200 mcg MK-7 daily alongside vitamin D supplementation, particularly at doses above 4,000 IU.

Some combination products bundle D3 + K2 (often labeled "Vitamin D3 + K2" or similar). These work but verify the K2 form is MK-7 (longer half-life, better-validated) rather than MK-4 (shorter half-life, less consistent dosing). Magnesium is usually taken separately — most combination D3 + K2 products don't include therapeutic magnesium doses.

How to Get 25-Hydroxyvitamin D Tested

Three paths to measurement:

Path 1: Function Health or comparable direct-to-consumer service. Function Health's advanced panel includes 25-hydroxyvitamin D alongside the broader biomarker set (~$500 for comprehensive panel, no physician order needed). Results in 5-10 business days.

Path 2: Request from your primary care physician. 25-hydroxyvitamin D is one of the more commonly-ordered vitamin tests at primary care. Most insurance plans cover it once per year for adults with risk factors (older age, dark skin, limited sun exposure, malabsorption history). Out-of-pocket cost: $30-100.

Path 3: Standalone direct test. Quest Diagnostics, LabCorp, and direct-to-consumer services (Walk-In Lab, etc.) offer standalone 25-hydroxyvitamin D testing for $40-80 without physician order in most US states.

The pragmatic measurement cadence: baseline test before starting supplementation, retest at 12 weeks to confirm the dose is moving serum levels appropriately, then annually for maintenance tracking. Adults running aggressive supplementation protocols (5,000+ IU daily) may benefit from biannual testing to catch any over-correction early.

What VITAL and the Recent Trial Data Actually Show

The 2018 VITAL trial (Manson et al.) tested 2,000 IU daily vitamin D3 in 25,871 generally-healthy US adults over 5.3 years and found no reduction in invasive cancer or major cardiovascular events compared to placebo. This result has been overinterpreted in two directions.

The over-skeptical interpretation argues VITAL proves vitamin D supplementation doesn't work for longevity outcomes. The careful read: VITAL enrolled adults whose baseline 25-hydroxyvitamin D was already in the 30 ng/mL range on average — meaning most subjects were already in the IOM-sufficient zone. The 2,000 IU intervention raised them modestly but didn't produce dramatic Index changes in already-sufficient adults. The cohort literature on vitamin D effects is concentrated in the deficient-to-sufficient transition, not in incremental movement within the sufficient zone.

The over-enthusiastic interpretation claims VITAL was flawed and the cohort data should still drive aggressive supplementation. The careful read: VITAL is consistent with the targeted-intervention framework — vitamin D supplementation meaningfully benefits adults who start deficient; the benefit is smaller in adults who start sufficient.

The integrated framework that emerges: test, target, retest. Adults whose 25-hydroxyvitamin D is below 30 ng/mL benefit substantially from supplementation. Adults already above 40 ng/mL benefit minimally from incremental supplementation. The intervention isn't blanket vitamin D dosing — it's calibrated correction of measured deficiency.

Integration With the Broader Biomarker Stack

25-hydroxyvitamin D sits in the broader advanced biomarker panel alongside:

• apoB and Lp(a) — cardiovascular particle and genetic risk markers
• Omega-3 Index — marine omega-3 cardiovascular and cognitive marker
• hs-CRP — systemic inflammation
• Fasting insulin and HOMA-IR — metabolic-cardiovascular linkage
• Homocysteine — modifiable cardiovascular and cognitive risk factor
• Full advanced panel — the integrated longevity biomarker stack

The CGM data (covered in our CGM deep dive) provides the daily metabolic context. The Decode Your Biology protocol guide covers the full panel, the optimal thresholds for each marker, and the intervention-by-intervention retest cadence.

The Bottom Line

Vitamin D is one of the simplest, cheapest, and most-evidence-backed interventions in the entire longevity biomarker panel. The deficiency is widespread (40 percent of US adults). The test is inexpensive ($40-80 standalone, often covered by insurance). The intervention is cheap (D3 supplements cost under $50/year at therapeutic doses). The dose-response is well-characterized. The retest cadence is workable (baseline → 12 weeks → annual).

The honest framing: the 600 IU RDA prevents rickets in vitamin-D-naive adults; it does not optimize the 25-hydroxyvitamin D status that the modern longevity literature increasingly emphasizes. Adults who are willing to test once, dose appropriately to move serum levels into the 40-60 ng/mL range, retest to confirm, and add the K2 and magnesium cofactors capture the most well-validated nutrient-intervention benefit available to the average non-clinical adult.

Most adults have not measured. The marginal value of measurement is high. The cost of the intervention is low. This is the kind of asymmetric decision longevity protocols are designed to operationalize.

This article is part of the PureLongevity research library. Nothing here constitutes medical advice. Vitamin D supplementation interactions with hypercalcemia, kidney disease, granulomatous disorders (sarcoidosis), and certain other clinical contexts require physician supervision. Always verify with a qualified clinician before changing a supplement protocol. PureLongevityToday may earn a commission from purchases made through links in this article.